Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277914 | 0.84 | PLA2G7 (0.67) | PLA2G7S1PR4KMT2AMEN1TP53 | |
| SCHEMBL277702 | 0.80 | PBRM1 (0.44) | PLA2G7S1PR4KMT2AMEN1TP53 | |
| SCHEMBL8819360 | 0.79 | P2RX7 (0.46) | PLA2G7NUDT1ELANEP2RX7NOTUM | |
| SCHEMBL10343150 | 0.77 | PLA2G7 (0.47) | PLA2G7S1PR4KMT2AMEN1TP53 | |
| SCHEMBL848308 | 0.77 | PLA2G7 (0.44) | PLA2G7S1PR4KMT2AMEN1TP53 | |
| SCHEMBL197716 | 0.76 | ALDH1A1 (0.52) | S1PR4KMT2AMEN1TP53MAPT | |
| SCHEMBL440943 | 0.76 | TSHR (0.52) | NUDT1P2RX7NOTUMIDO1 | |
| SCHEMBL277747 | 0.74 | ELANE (0.52) | PLA2G7S1PR4KMT2AMEN1TP53 | |
| SCHEMBL8817721 | 0.74 | ACHE (0.42) | NUDT1PBRM1PTGES2 | |
| SCHEMBL28219402 | 0.74 | PLA2G7 (0.46) | PLA2G7TP53MAPTELANEIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247969-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200290966-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-17 | — | — | US | disclosed |
| US-10570092-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-10343995-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190047957-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-14 | — | — | US | disclosed |
| US-10106503-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180179161-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-06-28 | — | — | US | disclosed |
| US-9926272-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170204061-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-07-20 | — | — | US | disclosed |
| US-9452161-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-09-27 | — | — | US | disclosed |
| WO-2005087737-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087738-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087763-A1 | DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087735-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087733-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20050203134-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20050203139-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20050203167-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20050203138-A1 | Biphenylylaminocarbonyl-amino- or -oxypiperidine derivatives, e.g., biphenyl-2-ylcarbamic acid 1-[2-((4-[(4-hydroxybenzylamino)methyl]benzoyl)methylamino)ethyl]piperidin-4-yl ester; treating bronchodilation, asthma and chronic obstructive pulmonary disease (COPD) | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247969-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | PLA2G7 1413/4885NUDT1 1312/4885S1PR4 632/4885 |
| US-20170204061-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | PLA2G7 1413/4885NUDT1 1312/4885S1PR4 632/4885 |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | PLA2G7 1413/4885NUDT1 1312/4885S1PR4 632/4885 |
| US-20050203167-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM1, CHRM2, CHRM3 | PLA2G7 1488/4885NUDT1 2363/4885S1PR4 784/4885 |
| US-20190047957-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | PLA2G7 1413/4885NUDT1 1312/4885S1PR4 632/4885 |
| US-10343995-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | PLA2G7 1413/4885NUDT1 1312/4885S1PR4 632/4885 |
| US-10570092-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | PLA2G7 1413/4885NUDT1 1312/4885S1PR4 632/4885 |
| US-20050203138-A1 | Biphenylylaminocarbonyl-amino- or -oxypiperidine derivatives, e.g., biphenyl-2-ylcarbamic acid 1-[2-((4-[(4-hydroxybenzylamino)methyl]benzoyl)methylamino)ethyl]piperidin-4-yl ester; treating bronchodilation, asthma and chronic obstructive pulmonary disease (COPD) | CHRM1, CHRM2, CHRM3 | PLA2G7 909/4885NUDT1 1315/4885S1PR4 374/4885 |
| US-10106503-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | PLA2G7 1413/4885NUDT1 1312/4885S1PR4 632/4885 |
| US-20050203139-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM1, CHRM2, CHRM3 | PLA2G7 1141/4885NUDT1 1728/4885S1PR4 487/4885 |
| US-20200290966-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | PLA2G7 1413/4885NUDT1 1312/4885S1PR4 632/4885 |
| US-20050203134-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | PLA2G7 1483/4885NUDT1 1323/4885S1PR4 543/4885 |
| US-20180179161-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | PLA2G7 1413/4885NUDT1 1312/4885S1PR4 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.